ENDOTHELIAL LIPASE AS NEW DIAGNOSTIC MARKER OF NON-ALCOHOLIC FATTY LIVER DISEASE IN HYPERTENSIVE SUBJECTS (review)
PDF

How to Cite

Bashkirova, A. (2018). ENDOTHELIAL LIPASE AS NEW DIAGNOSTIC MARKER OF NON-ALCOHOLIC FATTY LIVER DISEASE IN HYPERTENSIVE SUBJECTS (review). Inter Collegas, 5(2), 57-63. https://doi.org/10.35339/ic.5.2.57-63

Abstract

ENDOTHELIAL LIPASE AS NEW DIAGNOSTIC MARKER OF NON-ALCOHOLIC FATTY LIVER DISEASE IN HYPERTENSIVE SUBJECTS (review)

Bashkirova A.D

Non-alcoholic fatty liver disease  (NAFLD) and hypertension are among the most common diseases in the world. One of the negative factors  contributing to the formation of cardiovascular risk in patients with NAFLD affected with hypertension is the low level of HDL cholesterol in which metabolism endothelial lipase (EL) plays a leading role. Therefore, it is very relevant and expedient to study the various aspects of the use of EL to diagnose NAFLD and determe treatment strategy in patients with NAFLD and hypertension.

Key words: non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, hypertension, endothelial lipase, lipid metabolism, overweight.

 

ЕНДОТЕЛІАЛЬНА ЛІПАЗА ЯК НОВИЙ ДІАГНОСТИЧНИЙ МАРКЕР НЕАЛКОГОЛЬНИЙ ЖИРОВОЇ ХВОРОБИ ПЕЧІНКИ (НАЖХП) У ОСІБ З ГІПЕРТЕНЗІЄЮ (огляд)

Башкірова А.Д.

НАЖХП і гіпертонічна хвороба є одними з найпоширеніших хвороб у світі. Одним з несприятливих факторів, що сприяють формуванню кардіоваскулярного ризику у пацієнтів з НАЖБП на тлі гіпертонічної хвороби, є низький рівень холестерину ЛПВЩ, в метаболізмі якого грає провідну роль активність ендотеліальної ліпази. Тому досить актуальним і доцільним є вивчення різних аспектів використання ЕЛ для діагностики НАЖБП з подальшим визначенням лікувальної тактики у хворих НАЖХП на тлі ГХ.

Ключові слова: неалкогольна жирова хвороба печінки, неалкогольний стеатогепатит, гіпертонічна хвороба, ендотеліальналіпаза, ліпіднийобмін, надлишковамасатіла .

 

ЭНДОТЕЛИАЛЬНАЯ ЛИПАЗА КАК НОВЫЙ ДИАГНОСТИЧЕСКИЙ МАРКЕР НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ (НАЖБП)У ЛИЦ С ГИПЕРТЕНЗИЕЙ (обзор)

Башкирова А.Д.

НАЖБП и гипертоническая болезнь являются одними из самых распространенных болезней в мире. Одним из неблагоприятных факторов, способствующих формированию кардиоваскулярного риска у пациентов с НАЖБП на фоне гипертонической болезни, является низкий уровень холестерина ЛПВП, в метаболизме которого играет ведущую роль активность эндотелиальной липазы. Поэтому весьма актуальным и целесообразным является изучение различных аспектов использования ЭЛ для диагностики НАЖБП с последующим определением лечебной тактики у больных НАЖБП на фоне ГБ. 

Ключевые слова: неалкогольная жировая болезнь печени, неалкогольный стеатогепатит, гипертоническая болезнь, эндотелиальная липаза, липидный обмен, избыточная масса тела.


https://doi.org/10.35339/ic.5.2.57-63
PDF

References

Lee Y.J., Shim J.Y., Moon B.S., Shin Y.H., Jung D.H., …, Lee H.R. (2012). The relationship between arterial stiffness and nonalcoholic fatty liver disease. Dig Dis Sci. V.57:196-203.

Kosobyan E.P., Smirnova O.M. (2010). Sovremennyie kontseptsii patogeneza nealkogolnoy zhirovoy bolezni pecheni. Saharnyiy diabet. Vol.1:55-64.

Liu H., Lu H-Y. (2014). Nonalcoholic fatty liver disease and cardiovascular disease. World J Gastroenterol. V.20(26):8407-8415.

Alkhouri N., Kistangari G., Campbell C., Lopez R., Zein N.N., Feldstein A.E. (2012). Mean platelet volume as a marker of increased cardiovascular risk in patients with nonalcoholic steatohepatitis. Hepatology. V.55:331.

Dam-Larsen S., Becker U., Franzmann M.B., Larsen K., Christoffersen P., Bendtsen F. (2009). Final results of a long-term, clinical follow-up in fatty liver patients. Scandinavian Journal of Gastroenterology. V.44(10):1236-1243.

Alkhouri N., Tamimi T.A.R., Yerian L., Lopez R., Zein N.N., Feldstein A.E. (2010). The inflamed liver and atherosclerosis: a Link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk. Digestive Diseases and Sciences. V.55(9:2644-2650.

Chon YE, Kim KJ, Jung KS, Kim SU, Park JY, …, Han KH. (2016). The Relationship between Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Measured by Controlled Attenuation Parameter. Yonsei Med J. 57(4):885-92. doi: 10.3349/ymj.2016.57.4.885. PubMed Central PMCID: PMC4951464.

Ramilli S., Pretolani S., Muscari A., Pacelli B., Arienti V. (2009). Carotid lesions in outpatients with nonalcoholic fatty liver disease. World Journal of Gastroenterology. V.15(38):4770-4774.

Mansia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, …, Zanchetti A. (2007). ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press. 16(3):135-232. PubMed PMID: 17846925.

Haffner SM. (2000). Obesity and the metabolic syndrome: the San Antonio Heart Study. Br J Nutr. 83 Suppl 1:S67-70. PubMed PMID: 10889794.

Gerasimova A.S., Oleynikov V.E. (2010). Osobennosti medikamentoznoy korrektsii arterialьnoy gipertenzii pri metabolicheskom sindrome. Zhurnal Izvestiya vyisshih uchebnyih zavedeniy. Povolzhskiy region. V.1:106-119.

Madan SA, John F, Pyrsopoulos N, Pitchumoni CS. (2015). Nonalcoholic fatty liver disease and carotid artery atherosclerosis in children and adults: meta-analysis. Eur J Gastroenterol Hepatol. 27(11):1237-48. doi: 10.1097/MEG.0000000000000429. PubMed PMID: 26193052.

Suzuki T., Hirata K., Elkind M.S. et al. (2008). Metabolic syndrome, endothelial dysfunction, and risk of cardiovascular events: the Nordhern Manhattan Study (NOMAS). Am. Heart.J. Vol. 156:405.

Schindhelm R.K., Dekker J.M., Nijpels G. et al. (2007). Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis. V.191(2):391-396.

Wang C.C., Tseng Y.F. et al. (2009). Elevation of serum aminotransferase activity increases risk of carotid atherosclerosis in patients with non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology. V.24(8):1411-1416.

Ioannou G.N., Weiss N.S., Boyko E.J., Mozaffarian D., Lee S.P. (2006). Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology. V.43(5):1145-1151.

Monami M., Bardini G., Lamanna C. et al. (2008). Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism. V.57(3):387-392.

Lopez-Suarez A., Guerrero M., Elvira-Gonzalez J., Beltran-Robles M., Canas-Hormigo F., Bascunana-Quirell A. (2011). Nonalcoholic fatty liver disease is associated with blood pressure in hypertensive and nonhypertensive individ-uals from the general population with normal levels of alanine aminotransferase. European Journal of Gastroenterology and Hepatology. V.23(11):1011-1017.

Feitosa M.F., Reiner A.P., Wojczynski M.K., Graff M., North K.E., Carr J.J., Borecki I.B. (2013). Sex-influenced association of nonalcoholic fatty liver disease with coronary heart disease. Atherosclerosis. 227:420-424.

De Filippis A.P., Blaha M.J., Martin S.S., Reed R.M., Jones S.R., …, Budoff M.J. (2013). Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. V.227:429-436.

Feitosa M.F., Reiner, M.K. Wojczynski, M. Graff, K.E. North, …, Borecki I.B. (2013). Sex-influenced association of nonalcoholic fatty liver disease with coronary heart disease Atherosclerosis. V.227:420-424.

Akın L., Kurtoglu S., Yikilmaz A., Kendirci M., Elmalı F., Mazicioglu M. (2013). Fatty liver is a good indicator of subclinical atherosclerosis risk in obese children and adolescents regardless of liver enzyme elevation. Acta Paediatr. V.102:107-113.

Catena C., Bernardi S., Sabato N., Grillo A., Ermani M., …, Fallo F. (2013). Ambulatory arterial stiffness indices and non-alcoholic fatty liver disease in essential hypertension. Nutr Metab Cardiovasc Dis. V.23:389-393.

Fracanzani A.L., Burdick L., Raselli S. et al. (2008). Carotid artery intima-media thickness in nonalcoholic fatty liver disease. American Journal of Medicine. V.121(1):72-78.

Cakır E., Ozbek M., Colak N., Cakal E., Delıbaşi T. (2012). Is NAFLD an independent risk factor for increased IMT in T2DM? Minerva Endocrinol. V.37:187-193.

Colak Y., Senates E., Yesil A., Yilmaz Y., Ozturk O., ..., Ulasoglu C. (2013). Assessment of endothelial function in patients with nonalcoholic fatty liver disease. Endocrine. V.43:100-107.

Bhatia L.S., Curzen N.P., Byrne C.D. (2012). Nonalcoholic fatty liver disease and vascular risk. Curr Opin Cardiol. V.27:420-428.

Butorova L.I., Kadnikova L.I., Kalashnikova M.A. (2014). Lekarstvennyie povrezhdeniya pecheniu patsientov s metabolicheskim sindromomi nealkogolnoy zhirovoy boleznyu pecheni:novyie vozmozhnosti profilaktiki i lecheniya. Meditsinskie novosti. V.8(239):41-47.

Bueverov A.O., Bogomolov P.O. (2012). «Tsitokinovyiy vzryiv» i progressirovanie nealkogolnogo steatogepatita. Klinicheskie perspektivyi gastroenterologii, gepatologii. V.5:12-18.

Heuer M., Kaiser G.M., Kahraman A., Banysch M., Saner F.H.,…, Treckmann J.W. (2012). Liver transplantation in non-alcoholic steatohepatitis is associated with high mortality and post-transplant complications: a single-center experience. Digestion. V.86:107-113.

Coracina A., Gaiani S., Cosma A., Pellizzari P., Pizzi C., …, Tessari P. (2012). No association between the degree of liver steatosis and early signs of vasculopathy in T2DM. Nutr Metab Cardiovasc Dis. V.22:11-12.

de Carvalho S.C., Muniz M.T., Siqueira M.D., Siqueira E.R., Gomes A.V., …, Pereira L.M. (2013). Plasmatic higher levels of homocysteine in non-alcoholic fatty liver disease (NAFLD). Nutr J. V.12:37.

Dogru T., Genc H., Tapan S., Ercin C.N., Ors F., …, Kurt I. (2012). Elevated asymmetric dimethylarginine in plasma: an early marker for endothelial dysfunction in non-alcoholic fatty liver disease? Diabetes Res Clin Pract. V.96:47-52.

Kaur J.A. (2014). Comprehensive Review on Metabolic Syndrome. Cardiol Res Pract. V.2014:943162.

Morioka, T., Emoto, M., Yamazaki, Y., Kawano, N., Imamura, S., Numaguchi, R., … Inaba, M. (2014). Leptin is associated with vascular endothelial function in overweight patients with type 2 diabetes. Cardiovascular Diabetology, 13, 10. http://doi.org/10.1186/1475-2840-13-10

Statsenko M.E., Turkina S.V., Evtereva E.D. (2012). Metabolicheskaya terapiya meldoniem: vozmozhnosti primeneniya v lechenii hronicheskoy serdechnoy nedostatochnosti u bolnyih s metabolicheskim sindromom. Consilium medicum. – 2012. V. 15:81-86.

Paradis, M.-E., & Lamarche, B. (2006). Endothelial lipase: Its role in cardiovascular disease. The Canadian Journal of Cardiology, 22(Suppl B), 31B–34B.

DiMarco, D. M., & Fernandez, M. L. (2015). The Regulation of Reverse Cholesterol Transport and Cellular Cholesterol Homeostasis by MicroRNAs. Biology, 4(3), 494–511. http://doi.org/10.3390/biology4030494

Miksztowicz V, McCoy MG, Schreier L, Cacciagiú L, Elbert A, …, Berg G. (2012). Endothelial lipase activity predicts high-density lipoprotein catabolism in hemodialysis: novel phospholipase assay in postheparin human plasma. Arterioscler Thromb Vasc Biol. 32(12):3033-40. doi: 10.1161/ATVBAHA.112.300110.

Shiu, S. W., Zhou, H., Wong, Y., & Tan, K. C. (2010). Endothelial lipase and reverse cholesterol transport in type 2 diabetes mellitus. Journal of Diabetes Investigation, 1(3), 111–116. http://doi.org/10.1111/j.2040-1124.2010.00016.x

Masakatsu Shimizu, Kenji Kanazawa, Ken-ichi Hirata et al. (2007). Endothelial Lipase Gene Polymorphism is Associated With Acute Myocardial Infarction, Independently of High-Density Lipoprotein-Cholesterol Levels. Circ J. V.71: 842 –846.

Badellino KO, Wolfe M, Dykhouse J, Rohatgi A, Reilly M, Rader DJ. (2004). Endothelial lipase is upregulated by inflammatory mediators and correlated with low рL levels seen in metabolic syndrome. Circulation. V.110:52.

Paradis M.E., Badellino K.O., Rader D.J., et al. (2004). Endothelial lipase, obesity and the metabolic syndrome. Arterioscler Thromb Vasc Biol. V.24:E6.

Razzaghi H, Tempczyk-Russell A, Haubold K, Santorico SA, Shokati T, et al. (2013) Genetic and Structure-Function Studies of Missense Mutations in Human Endothelial Lipase. PLoS ONE 8(3): e55716. doi:10.1371/journal.pone.0055716.

Griffon, N., Jin, W., Petty, T. J., Millar, J., Badellino, K. O., Saven, J. G., … Rader, D. J. (2009). Identification of the Active Form of Endothelial Lipase, a Homodimer in a Head-to-Tail Conformation. The Journal of Biological Chemistry, 284(35), 23322–23330. http://doi.org/10.1074/jbc.M109.037002

"Inter Collegas" is an open access journal: all articles are published in open access without an embargo period, under the terms of the CC BY-NC-SA (Creative Commons Attribution ‒ Noncommercial ‒ Share Alike) license; the content is available to all readers without registration from the moment of its publication. Electronic copies of the archive of journals are placed in the repositories of the KhNMU and V.I. Vernadsky National Library of Ukraine.